We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.
- Authors
Taher, Ali T.; Porter, John B.; Viprakasit, Vip; Kattamis, Antonis; Chuncharunee, Suporn; Sutcharitchan, Pranee; Siritanaratkul, Noppadol; Origa, Raffaella; Karakas, Zeynep; Habr, Dany; Zhu, Zewen; Cappellini, Maria Domenica
- Abstract
Liver iron concentration ( LIC) assessment by magnetic resonance imaging ( MRI) remains the gold standard to diagnose iron overload and guide iron chelation therapy in patients with non-transfusion-dependent thalassaemia ( NTDT). However, limited access to MRI technology and expertise worldwide makes it practical to also use serum ferritin assessments. The THALASSA (assessment of Exjade® in non-transfusion-dependent THALASSemiA patients) study assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients and provided a large data set to allow exploration of the relationship between LIC and serum ferritin. Using data from screened patients and those treated with deferasirox for up to 2 years, we identified clinically relevant serum ferritin thresholds (for when MRI is unavailable) for the initiation of chelation therapy (>800 μg/l), as well as thresholds to guide chelator dose interruption (<300 μg/l) and dose escalation (>2000 μg/l). (clinicaltrials.gov identifier: NCT00873041).
- Subjects
FERRITIN; DEFERASIROX; MAGNETIC resonance imaging; BLOOD diseases; CHELATION therapy; PATIENTS; THERAPEUTICS
- Publication
British Journal of Haematology, 2015, Vol 168, Issue 2, p284
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.13119